NanoViricides (NNVC)

Revenue in 2026 (TTM): N/A

In 2025 the company made a revenue of N/A a decrease over the revenue in the year 2024 that were of N/A. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for NanoViricides from 2009 to 2026

Annual revenue

Year	Revenue	Change
2026 (TTM)	N/A
2025	N/A
2024	N/A
2023	N/A
2022	N/A
2021	N/A
2020	N/A
2019	N/A
2018	N/A
2017	N/A
2016	N/A
2015	N/A
2014	N/A
2013	N/A
2012	N/A
2011	N/A
2010	N/A
2009	N/A

Revenue for similar companies or competitors

Company	Revenue	Revenue differencediff.	Country
Gilead Sciences GILD	₹2.870 T	N/A	🇺🇸 USA
Merck MRK	₹6.350 T	N/A	🇺🇸 USA
Bristol-Myers Squibb BMY	₹4.681 T	N/A	🇺🇸 USA
GSK plc GSK	₹4.264 T	N/A	🇬🇧 UK
Novavax NVAX	₹57.57 B	N/A	🇺🇸 USA
BioCryst Pharmaceuticals BCRX	₹85.51 B	N/A	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Revenue for NanoViricides (NNVC)

Revenue in 2026 (TTM): N/A